Pfizer withdraws menopause 'hot flashes' indication for Pristiq
This article was originally published in Scrip
Executive Summary
Pfizer has withdrawn its supplemental new drug application for its depression drug Pristiq (desvenlafaxine) as a treatment for moderate-to-severe vasomotor symptoms (VMS) associated with menopause, such as hot flashes and night sweats, the firm revealed in a filing with the US Securities and Exchange Commission.